Angiogenic gene therapy for experimental critical limb ischemia

Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2

Ichiro Masaki, Yoshikazu Yonemitsu, Akihisa Yamashita, Shihoko Sata, Mitsugu Tanii, Kimihiro Komori, Kazunori Nakagawa, Xiaogang Hou, Yoshiyuki Nagai, Mamoru Hasegawa, Keizo Sugimachi, Katsuo Sueishi

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Recent studies suggest the possible therapeutic effect of intramuscular vascular endothelial growth factor (VEGF) gene transfer in individuals with critical limb ischemia. Little information, however, is available regarding (1) the required expression level of VEGF for therapeutic effect, (2) the related expression of endogenous angiogenic factors, including fibroblast growth factor-2 (FGF-2), and (3) the related adverse effects due to overexpression of VEGF. To address these issues, we tested effects of overexpression of VEGF165 using recombinant Sendai virus (SeV), as directly compared with FGF-2 gene transfer. Intramuscular injection of SeV strongly boosted FGF-2, resulting in significant therapeutic effects for limb salvage with increased blood perfusion associated with enhanced endogenous VEGF expression in murine models of critical limb ischemia. In contrast, VEGF165 overexpression, 5-times higher than that of baseline on day 1, also strongly evoked endogenous VEGF in muscles, resulting in an accelerated limb amputation without recovery of blood perfusion. Interestingly, viable skeletal muscles of either VEGF165- or FGF-2-treated ischemic limbs showed similar platelet-endothelial cell adhesion molecule-1-positive vessel densities. Maturation of newly formed vessels suggested by smooth muscle cell actin-positive cell lining, however, was significantly disturbed in muscles with VEGF. Further, therapeutic effects of FGF-2 were completely diminished by anti-VEGF neutralizing antibody in vivo, thus indicating that endogenous VEGF does contribute to the effect of FGF-2. These results suggest that VEGF is necessary, but should be delicately regulated to lower expression to treat ischemic limb. The therapeutic effect of FGF-2, associated with the harmonized angiogenic effects seen with endogenous VEGF, provides important insights into therapeutic angiogenesis.

Original languageEnglish
Pages (from-to)966-973
Number of pages8
JournalCirculation research
Volume90
Issue number9
DOIs
Publication statusPublished - May 17 2002

Fingerprint

Fibroblast Growth Factor 2
Genetic Therapy
Vascular Endothelial Growth Factor A
Ischemia
Extremities
Therapeutic Uses
Sendai virus
Fibroblast Growth Factor 3
Perfusion
human VEGFA protein
CD31 Antigens
Muscles
Limb Salvage
Angiogenesis Inducing Agents
Intramuscular Injections
Neutralizing Antibodies
Amputation
Genes
Smooth Muscle Myocytes
Actins

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Angiogenic gene therapy for experimental critical limb ischemia : Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. / Masaki, Ichiro; Yonemitsu, Yoshikazu; Yamashita, Akihisa; Sata, Shihoko; Tanii, Mitsugu; Komori, Kimihiro; Nakagawa, Kazunori; Hou, Xiaogang; Nagai, Yoshiyuki; Hasegawa, Mamoru; Sugimachi, Keizo; Sueishi, Katsuo.

In: Circulation research, Vol. 90, No. 9, 17.05.2002, p. 966-973.

Research output: Contribution to journalArticle

Masaki, Ichiro ; Yonemitsu, Yoshikazu ; Yamashita, Akihisa ; Sata, Shihoko ; Tanii, Mitsugu ; Komori, Kimihiro ; Nakagawa, Kazunori ; Hou, Xiaogang ; Nagai, Yoshiyuki ; Hasegawa, Mamoru ; Sugimachi, Keizo ; Sueishi, Katsuo. / Angiogenic gene therapy for experimental critical limb ischemia : Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. In: Circulation research. 2002 ; Vol. 90, No. 9. pp. 966-973.
@article{7e18eedb5bf24727a9ba723ceecc2dd8,
title = "Angiogenic gene therapy for experimental critical limb ischemia: Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2",
abstract = "Recent studies suggest the possible therapeutic effect of intramuscular vascular endothelial growth factor (VEGF) gene transfer in individuals with critical limb ischemia. Little information, however, is available regarding (1) the required expression level of VEGF for therapeutic effect, (2) the related expression of endogenous angiogenic factors, including fibroblast growth factor-2 (FGF-2), and (3) the related adverse effects due to overexpression of VEGF. To address these issues, we tested effects of overexpression of VEGF165 using recombinant Sendai virus (SeV), as directly compared with FGF-2 gene transfer. Intramuscular injection of SeV strongly boosted FGF-2, resulting in significant therapeutic effects for limb salvage with increased blood perfusion associated with enhanced endogenous VEGF expression in murine models of critical limb ischemia. In contrast, VEGF165 overexpression, 5-times higher than that of baseline on day 1, also strongly evoked endogenous VEGF in muscles, resulting in an accelerated limb amputation without recovery of blood perfusion. Interestingly, viable skeletal muscles of either VEGF165- or FGF-2-treated ischemic limbs showed similar platelet-endothelial cell adhesion molecule-1-positive vessel densities. Maturation of newly formed vessels suggested by smooth muscle cell actin-positive cell lining, however, was significantly disturbed in muscles with VEGF. Further, therapeutic effects of FGF-2 were completely diminished by anti-VEGF neutralizing antibody in vivo, thus indicating that endogenous VEGF does contribute to the effect of FGF-2. These results suggest that VEGF is necessary, but should be delicately regulated to lower expression to treat ischemic limb. The therapeutic effect of FGF-2, associated with the harmonized angiogenic effects seen with endogenous VEGF, provides important insights into therapeutic angiogenesis.",
author = "Ichiro Masaki and Yoshikazu Yonemitsu and Akihisa Yamashita and Shihoko Sata and Mitsugu Tanii and Kimihiro Komori and Kazunori Nakagawa and Xiaogang Hou and Yoshiyuki Nagai and Mamoru Hasegawa and Keizo Sugimachi and Katsuo Sueishi",
year = "2002",
month = "5",
day = "17",
doi = "10.1161/01.RES.0000019540.41697.60",
language = "English",
volume = "90",
pages = "966--973",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Angiogenic gene therapy for experimental critical limb ischemia

T2 - Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2

AU - Masaki, Ichiro

AU - Yonemitsu, Yoshikazu

AU - Yamashita, Akihisa

AU - Sata, Shihoko

AU - Tanii, Mitsugu

AU - Komori, Kimihiro

AU - Nakagawa, Kazunori

AU - Hou, Xiaogang

AU - Nagai, Yoshiyuki

AU - Hasegawa, Mamoru

AU - Sugimachi, Keizo

AU - Sueishi, Katsuo

PY - 2002/5/17

Y1 - 2002/5/17

N2 - Recent studies suggest the possible therapeutic effect of intramuscular vascular endothelial growth factor (VEGF) gene transfer in individuals with critical limb ischemia. Little information, however, is available regarding (1) the required expression level of VEGF for therapeutic effect, (2) the related expression of endogenous angiogenic factors, including fibroblast growth factor-2 (FGF-2), and (3) the related adverse effects due to overexpression of VEGF. To address these issues, we tested effects of overexpression of VEGF165 using recombinant Sendai virus (SeV), as directly compared with FGF-2 gene transfer. Intramuscular injection of SeV strongly boosted FGF-2, resulting in significant therapeutic effects for limb salvage with increased blood perfusion associated with enhanced endogenous VEGF expression in murine models of critical limb ischemia. In contrast, VEGF165 overexpression, 5-times higher than that of baseline on day 1, also strongly evoked endogenous VEGF in muscles, resulting in an accelerated limb amputation without recovery of blood perfusion. Interestingly, viable skeletal muscles of either VEGF165- or FGF-2-treated ischemic limbs showed similar platelet-endothelial cell adhesion molecule-1-positive vessel densities. Maturation of newly formed vessels suggested by smooth muscle cell actin-positive cell lining, however, was significantly disturbed in muscles with VEGF. Further, therapeutic effects of FGF-2 were completely diminished by anti-VEGF neutralizing antibody in vivo, thus indicating that endogenous VEGF does contribute to the effect of FGF-2. These results suggest that VEGF is necessary, but should be delicately regulated to lower expression to treat ischemic limb. The therapeutic effect of FGF-2, associated with the harmonized angiogenic effects seen with endogenous VEGF, provides important insights into therapeutic angiogenesis.

AB - Recent studies suggest the possible therapeutic effect of intramuscular vascular endothelial growth factor (VEGF) gene transfer in individuals with critical limb ischemia. Little information, however, is available regarding (1) the required expression level of VEGF for therapeutic effect, (2) the related expression of endogenous angiogenic factors, including fibroblast growth factor-2 (FGF-2), and (3) the related adverse effects due to overexpression of VEGF. To address these issues, we tested effects of overexpression of VEGF165 using recombinant Sendai virus (SeV), as directly compared with FGF-2 gene transfer. Intramuscular injection of SeV strongly boosted FGF-2, resulting in significant therapeutic effects for limb salvage with increased blood perfusion associated with enhanced endogenous VEGF expression in murine models of critical limb ischemia. In contrast, VEGF165 overexpression, 5-times higher than that of baseline on day 1, also strongly evoked endogenous VEGF in muscles, resulting in an accelerated limb amputation without recovery of blood perfusion. Interestingly, viable skeletal muscles of either VEGF165- or FGF-2-treated ischemic limbs showed similar platelet-endothelial cell adhesion molecule-1-positive vessel densities. Maturation of newly formed vessels suggested by smooth muscle cell actin-positive cell lining, however, was significantly disturbed in muscles with VEGF. Further, therapeutic effects of FGF-2 were completely diminished by anti-VEGF neutralizing antibody in vivo, thus indicating that endogenous VEGF does contribute to the effect of FGF-2. These results suggest that VEGF is necessary, but should be delicately regulated to lower expression to treat ischemic limb. The therapeutic effect of FGF-2, associated with the harmonized angiogenic effects seen with endogenous VEGF, provides important insights into therapeutic angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0037123968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037123968&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000019540.41697.60

DO - 10.1161/01.RES.0000019540.41697.60

M3 - Article

VL - 90

SP - 966

EP - 973

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 9

ER -